Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Uridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.88 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.88 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.88 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.88 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.62 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.58 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.57 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine SCHEMBL6288554 | 1.00 | SLC28A1 (0.88) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL4081077 | 0.96 | SLC28A1 (0.90) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL1495318 | 0.95 | SLC28A1 (0.83) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL6926760 | 0.94 | SLC28A1 (0.85) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2056634 | 0.94 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2912983 | 0.94 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL4455604 | 0.94 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL20987631 | 0.94 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2056530 | 0.94 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL9945547 | 0.94 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4453194-A1 | METHOD FOR THE SYNTHESIS OF A CARBONYL-FUNCTIONALISED ADDUCT | BRAIN Biotech AG (DE) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023118363-A1 | METHOD FOR THE SYNTHESIS OF A CARBONYL-FUNCTIONALISED ADDUCT | BRAIN Biotech AG (DE) | 2023-06-29 | — | — | WO | disclosed |
| CN-115666587-A | N4-hydroxycytidine and derivatives and related antiviral uses thereof | 埃默里大学 | 2023-01-31 | — | — | CN | disclosed |
| CN-107427510-A | Use of plinabulin in combination with an immune checkpoint inhibitor | 万春药业公司 | 2017-12-01 | — | — | CN | disclosed |
| US-20070160554-A1 | Acyl ribonucleosides and acyl deoxyribonucleosides, compositions of, and methods of making same | COGNIS IP MANAGEMENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| EP-1680435-A1 | ACYL RIBONUCLEOSIDES AND ACYL DEOXYRIBONUCLEOSIDES | Cognis IP Management GmbH (DE) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005049633-A1 | ACYL RIBONUCLEOSIDES AND ACYL DEOXYRIBONUCLEOSIDES | COGNIS IP MANAGEMENT GMBH (DE) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070160554-A1 | Acyl ribonucleosides and acyl deoxyribonucleosides, compositions of, and methods of making same | RNASEL, RNASEH1, DUT | SLC28A1 1568/4885SLC28A2 1262/4885SLC29A1 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.